文献速递呼吸道感染呼吸危重症与机械通气

重症流感与COVID-19患者肺部细菌谱及曲霉感染比较

Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

该回顾性研究纳入机械通气的流感与COVID-19患者,比较肺部细菌微生物组组成及其与病毒、真菌感染、免疫和结局的关联。结果显示流感患者曲霉检出率高于细菌病原体,细菌病原体仅与流感患者(尤其IAPA)90天死亡率相关,COVID-19患者对细菌病原体呈现更强的促炎细胞因子反应。

要点

  • 重症流感患者肺部曲霉检出率(38%)高于细菌病原体检出率(20%)。
  • 细菌病原体检出与流感患者90天死亡率相关,尤其合并IAPA者。
  • COVID-19患者细菌病原体检出率37%,但未显示与死亡率相关。

核心结论

  • 重症流感患者肺部曲霉检出较细菌病原体更常见。
  • 细菌病原体检出与流感患者不良结局相关, particularly IAPA,但与COVID-19患者无关。
  • COVID-19患者对细菌病原体呈现增强的促炎肺细胞因子反应。

研究设计与样本

  • 回顾性研究,纳入机械通气的流感与COVID-19患者,伴或不伴侵袭性曲霉病。
  • 纳入ICU入科2周内获取BAL进行细菌培养(伴或不伴PCR)的患者。
  • 对部分患者及需无创通气患者的BAL样本进行16S rRNA基因测序及病毒和细菌载量分析。
  • 整合16S rRNA基因测序数据与现有免疫参数数据集。

主要发现

  • 流感患者潜在细菌病原体检出率20%(28/142),COVID-19患者37%(104/281)。
  • 流感患者曲霉检出率38%(54/142),COVID-19患者31%(86/281)。
  • BAL液中细菌病原体与90天死亡率显著相关仅见于流感患者, particularly IAPA。
  • COVID-19患者(而非流感患者)对细菌病原体显示增强的促炎肺细胞因子反应。

临床怎么用

  • 重症流感患者应关注曲霉感染风险,其检出率高于细菌病原体。
  • 流感患者检出细菌病原体提示预后较差,尤其合并IAPA时需加强评估。
  • COVID-19患者细菌病原体检出与死亡率无关,临床解读需结合免疫反应背景。

局限性

  • 回顾性研究设计。
  • 16S rRNA基因测序及免疫参数分析仅基于部分患者子集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The influence of the lung bacterial microbiome, including potential pathogens, in patients with influenza-associated pulmonary aspergillosis (IAPA) or coronavirus disease (COVID-19)-associated pulmonary aspergillosis (CAPA) has yet to be explored. Objectives: To explore the composition of the lung bacterial microbiome and its association with viral and fungal infection, immunity, and outcome in severe influenza versus COVID-19 with or without aspergillosis. Methods: We performed a retrospective study in mechanically ventilated patients with influenza and COVID-19 with or without invasive aspergillosis in whom BAL for bacterial culture (with or without PCR) was obtained within 2 weeks after ICU admission. In addition, 16S rRNA gene sequencing data and viral and bacterial load of BAL samples from a subset of these patients, and of patients requiring noninvasive ventilation, were analyzed. We integrated 16S rRNA gene sequencing data with existing immune parameter datasets. Measurements and Main Results: Potential bacterial pathogens were detected in 20% (28/142) of patients with influenza and 37% (104/281) of patients with COVID-19, whereas aspergillosis was detected in 38% (54/142) of patients with influenza and 31% (86/281) of patients with COVID-19. A significant association between bacterial pathogens in BAL fluid and 90-day mortality was found only in patients with influenza, particularly patients with IAPA. Patients with COVID-19, but not patients with influenza, showed increased proinflammatory pulmonary cytokine responses to bacterial pathogens. Conclusions: Aspergillosis is more frequently detected in the lungs of patients with severe influenza than bacterial pathogens. Detection of bacterial pathogens associates with worse outcome in patients with influenza, particularly in those with IAPA, but not in patients with COVID-19. The immunological dynamics of tripartite viral-fungal-bacterial interactions deserve further investigation.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Feys S, Cardinali-Benigni M, Lauwers HM, et al. Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis. Am J Respir Crit Care Med. 2024. PMID: 38865563. doi:10.1164/rccm.202401-0145OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。